VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August3, 2018, the Board of Directors of VIVUS,Inc., or the Company, appointed Kenneth Suh to serve as the Company’s President, effective immediately. On the same day, Mr.Suh, age 43, resigned as the President and Chief Executive Officer and as a director of Willow Biopharma Inc., the Company’s wholly owned subsidiary. Mr.Suh founded Willow Biopharma Inc., a biopharmaceutical company, in 2015 and has served as the President and Chief Executive Officer and as a director from August2015 to August2018. In April2018, Willow Biopharma Inc. became a wholly owned subsidiary of the Company, and Mr.Suh was reappointed as the President and Chief Executive Officer and as a director of Willow Biopharma Inc. Mr.Suh also founded KRIM Biopharma Inc., a biopharmaceutical company, in 2013 and served as the President and Chief Executive Officer from August2013 to August2015 and as a director from August2013 to August2015. Mr.Suh held the following roles for Novartis Pharma Canada, a pharmaceutical company: Franchise Lead from 2012 to 2013, Brand Manager from 2010 to 2012, Associate Brand Manager from 2009 to 2010 and Medical Representative from 2006 to 2009. He received a Bachelor of Commerce, Honors Program from the University of Guelph, Ontario.

As the President and Chief Executive Officer of Willow Biopharma Inc., Mr.Suh previously received an annual base salary of $587,000 CAD, with a target bonus for 2018 equal to 50% of his base salary and an option to purchase 1,700,000 shares of the Company’s Common Stock under the Company’s 2018 Inducement Equity Incentive Plan. As President of the Company, Mr.Suh will receive an annual base salary of $460,000 USD, with a target bonus equal to 50% of his base salary. He will continue to vest under his previously granted stock option to purchase 1,700,000 shares of the Company’s Common Stock under the Company’s 2018 Inducement Equity Incentive Plan and previously granted stock option to purchase 200,000 shares of the Company’s Common Stock under the previously disclosed 2018 Bonus Plan.

On April30, 2018, the Company’s wholly own subsidiary, Willow Biopharma Inc., entered into a Change of Control and Severance Agreement with Mr.Suh, effective as of April30, 2018. On August3, 2018, the Company entered into the Third Amended and Restated Change of Control and Severance Agreement, or the Amended Severance Agreement, with Mr.Suh, on substantially the same terms as the Amended Severance Agreement entered into with each of our other executive officers. The Amended Severance Agreement superseded the Change of Control and Severance Agreement Mr.Suh previously entered into with Willow Biopharma Inc.

There were no arrangements or understandings between Mr.Suh and any other persons to which he was selected as an officer. There are no family relationships between Mr.Suh and any director or executive officer of the Company. As the former President and Chief Executive Officer and a former shareholder of Willow Biopharma Inc., on April30, 2018, Mr.Suh received (i)a warrant to purchase up to 2,151,000 shares of the Company’s Common Stock, with a per share exercise price of $0.37, (ii)a stock option to purchase 200,000 shares of the Company’s Common Stock granted to the 2018 Bonus Plan, and (iii)a stock option to purchase 1,700,000 shares of the Company’s Common Stock granted to the Company’s 2018 Inducement Equity Incentive Plan, and on July13, 2018, he received $500,000 for consulting services previously rendered to Willow Biopharma Inc., each in connection with the previously disclosed acquisition of Willow Biopharma Inc. He has no other direct or indirect material interest in any transaction required to be disclosed under Item 404(a)of Regulation S-K.

A copy of the form of Amended Severance Agreement will be filed as an exhibit to the Company’s Quarterly Report on Form10-Q for the quarter ending June30, 2018. The previously disclosed description of the Amended Severance Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.

Item 7.01. Regulation FD Disclosure

On August6, 2018, VIVUS,Inc. issued a press release titled “VIVUS Appoints Kenneth Suh as President.” A copy of the press release is attached hereto as Exhibit99.1.

The information furnished under this Item 7.01, including the related exhibit, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by reference to such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.


VIVUS INC Exhibit
EX-99.1 2 a18-18322_1ex99d1.htm EX-99.1 Exhibit 99.1     VIVUS Appoints Kenneth Suh as President   CAMPBELL,…
To view the full exhibit click here

About VIVUS,INC. (NASDAQ:VVUS)

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

An ad to help with our costs